Efavirenz and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Efavirenz
No brand names on recordCariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Efavirenz is an HIV medicine that speeds up a liver enzyme (called CYP3A4). Your body uses that same enzyme to both build up and break down the active parts of cariprazine (Vraylar), which treats conditions like bipolar disorder and schizophrenia. Because efavirenz can rev up that enzyme, it may change how much active cariprazine ends up in your body. Honestly, researchers haven't measured exactly how this plays out, so the net effect is uncertain. That's why taking them together isn't recommended.
The good news: your care team can manage this. Please don't stop either medicine on your own, just talk with your doctor or pharmacist so they can choose the safest plan for you.
Mechanism: Efavirenz is a CYP3A4 inducer; cariprazine is a CYP3A4 substrate. Because CYP3A4 governs both formation and elimination of cariprazine's active metabolites (didesmethyl-cariprazine), the net PK impact of induction is difficult to predict.
- Direction: Net effect on active-moiety exposure is unclear (not simply reduced).
- Magnitude/onset: Not quantified; enzyme induction typically develops over 1 to 2 weeks. Evidence is theoretical.
- Severity: Major; coadministration is not recommended.
- Management: Avoid the combination where possible. If used, monitor closely for loss of efficacy or emergent adverse effects, and individualize therapy with the prescriber.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
Using cariprazine (which is a substrate of CYP3A4) together with a CYP3A4 inducer is advised against. The generation as well as the clearance of cariprazine's active metabolites depend on CYP3A4. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall outcome remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
Combining efavirenz with cariprazine (Vraylar) is generally not recommended because the overall effect on cariprazine is unpredictable. Here is how a care team typically handles this:
- They may choose an alternative for one of the drugs when possible.
- If both are needed, your dose may be adjusted and individualized, and you may be monitored more closely for either reduced benefit or new side effects.
What you should do: keep taking both exactly as prescribed unless your prescriber tells you otherwise, and let your pharmacist or doctor know you are on both so they can review your plan.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Efavirenz and Cariprazine together?
Efavirenz can unpredictably change cariprazine levels, so the combination is not recommended; don't stop either drug on your own, but ask your doctor or pharmacist to review it. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Efavirenz and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Efavirenz and Cariprazine interaction managed?
Combining efavirenz with cariprazine (Vraylar) is generally not recommended because the overall effect on cariprazine is unpredictable. Here is how a care team typically handles this: They may choose an alternative for one of the drugs when possible. If both are needed, your dose may be adjusted and individualized, and you may be monitored more closely for either reduced benefit or new side effect… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Efavirenz or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Efavirenz
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist